ECSP034750A - Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 - Google Patents

Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7

Info

Publication number
ECSP034750A
ECSP034750A EC2003004750A ECSP034750A ECSP034750A EC SP034750 A ECSP034750 A EC SP034750A EC 2003004750 A EC2003004750 A EC 2003004750A EC SP034750 A ECSP034750 A EC SP034750A EC SP034750 A ECSP034750 A EC SP034750A
Authority
EC
Ecuador
Prior art keywords
inhibitors
spirocycles
phosphodiesterase
derivatives
new
Prior art date
Application number
EC2003004750A
Other languages
English (en)
Inventor
Patrick Bernardelli
Fabrice Vergne
Pierre Gerard Ducrot
Edwige Lorthiois
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164349&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP034750(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ECSP034750A publication Critical patent/ECSP034750A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La invención provee compuestos que son inhibidores de PDE7, que tienen las siguientes fórmulas (I), (II), (III): en donde X1, X2, X3, X4, X, Z A y Z1 son los definidos en la memoria descriptiva, métodos para prepararlos y su uso para el tratamiento de trastornos para los cuales la terapia con un inhibidor de PDE7 es relevante.
EC2003004750A 2001-03-21 2003-08-27 Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 ECSP034750A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/003355 WO2002076953A1 (en) 2001-03-21 2001-03-21 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors

Publications (1)

Publication Number Publication Date
ECSP034750A true ECSP034750A (es) 2003-10-28

Family

ID=8164349

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004750A ECSP034750A (es) 2001-03-21 2003-08-27 Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7

Country Status (47)

Country Link
US (3) US20020198198A1 (es)
EP (2) EP1801106A3 (es)
JP (1) JP4086663B2 (es)
KR (1) KR100617435B1 (es)
CN (1) CN100447136C (es)
AP (1) AP1699A (es)
AR (1) AR033617A1 (es)
AT (1) ATE367381T1 (es)
AU (1) AU2002304800B2 (es)
BG (1) BG108181A (es)
BR (1) BR0208192A (es)
CA (1) CA2441313C (es)
CU (1) CU23218A3 (es)
CY (1) CY1106829T1 (es)
CZ (1) CZ20032451A3 (es)
DE (1) DE60221233T2 (es)
DK (1) DK1373224T3 (es)
EA (1) EA006815B1 (es)
EC (1) ECSP034750A (es)
EE (1) EE200300459A (es)
ES (1) ES2288552T3 (es)
GE (1) GEP20053631B (es)
GT (1) GT200200053A (es)
HK (1) HK1061854A1 (es)
HR (1) HRP20030740A2 (es)
HU (1) HUP0303637A3 (es)
IL (2) IL157659A0 (es)
IS (1) IS2529B (es)
MA (1) MA27001A1 (es)
MX (1) MXPA03008485A (es)
MY (1) MY142045A (es)
NO (1) NO326086B1 (es)
NZ (1) NZ527847A (es)
OA (1) OA12454A (es)
PA (1) PA8541601A1 (es)
PE (1) PE20021010A1 (es)
PL (1) PL367058A1 (es)
PT (1) PT1373224E (es)
RS (1) RS50429B (es)
SI (1) SI1373224T1 (es)
SK (1) SK11562003A3 (es)
SV (1) SV2003000925A (es)
TN (1) TNSN03076A1 (es)
TW (1) TWI267509B (es)
UA (1) UA74243C2 (es)
WO (2) WO2002076953A1 (es)
ZA (1) ZA200306601B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
GB0230195D0 (en) * 2002-12-24 2003-02-05 Biofocus Plc Compound Libraries
EP1622569B1 (en) 2003-04-24 2015-12-02 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metallproteases
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
EP1656145A1 (en) * 2003-08-12 2006-05-17 F. Hoffmann-La Roche Ag Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
PL1775298T3 (pl) 2004-07-01 2013-08-30 Daiichi Sankyo Co Ltd Pochodna tienopirazolowa wykazująca aktywność hamowania PDE7
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
KR20070107099A (ko) * 2005-03-01 2007-11-06 화이자 리미티드 신경병증성 통증의 치료를 위한 pde7 억제제의 용도
GB0504209D0 (en) * 2005-03-01 2005-04-06 Pfizer Ltd New use of PDE7 inhibitors
KR100680497B1 (ko) * 2005-07-25 2007-02-08 엘지전자 주식회사 근거리통신 시스템에서 단말기가 액세스 포인트에 접속하는방법
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2377530A3 (en) 2005-10-21 2012-06-20 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
KR101009554B1 (ko) 2005-12-02 2011-01-18 화이자 리미티드 Pde7 억제제로서 스피로시클릭 퀴나졸린 유도체
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス,インコーポレイティド 4−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
CA2681650C (en) 2007-03-27 2016-11-22 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
CA2687944A1 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR20220047894A (ko) 2010-11-08 2022-04-19 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
PL3176170T3 (pl) 2012-06-13 2019-05-31 Incyte Holdings Corp Podstawione związki tricykliczne jako inhibitory fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PT2986610T (pt) 2013-04-19 2018-03-09 Incyte Holdings Corp Heterociclos bicíclicos como inibidores de fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2751669T3 (es) 2015-02-20 2020-04-01 Incyte Corp Heterociclos bicíclicos como inhibidores FGFR
WO2017101847A1 (zh) * 2015-12-16 2017-06-22 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮类似物、其晶型、其中间体及其制备方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN107382976A (zh) * 2017-07-04 2017-11-24 孙秀芹 一种治疗***的化合物及制备方法和应用
MX2020000295A (es) * 2017-07-12 2020-07-22 Dart Neuroscience Llc Compuestos de benzoxazol y benzofurano sustituidos como inhibidores de pde7.
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
KR20210018264A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 염
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PE20221085A1 (es) 2019-10-14 2022-07-05 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815979A (ja) 1981-07-11 1983-01-29 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体およびその製造法
US4764512A (en) 1986-08-27 1988-08-16 Rorer Pharmaceutical Corporation Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
HUT72076A (en) 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5602143A (en) * 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
BR9610988A (pt) * 1995-10-17 1999-04-06 Astra Pharma Prod Composto uso do mesmo fomulação farmacêutica e processo para produção do composto
CN1205008A (zh) * 1996-08-30 1999-01-13 协和发酵工业株式会社 咪唑并喹唑啉衍生物
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
PT1173210E (pt) 1999-05-04 2005-01-31 Ligand Pharm Inc Composicoes contraceptivas antiprogestativos e progestativos
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
WO2000066560A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
AU2274101A (en) 1999-12-21 2001-07-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
IS2529B (is) 2009-07-15
SV2003000925A (es) 2003-05-20
CN1498212A (zh) 2004-05-19
US7214676B2 (en) 2007-05-08
US20020198198A1 (en) 2002-12-26
NO326086B1 (no) 2008-09-15
GT200200053A (es) 2003-02-12
CU23218A3 (es) 2007-07-20
NO20034187L (no) 2003-10-15
AU2002304800B2 (en) 2007-08-30
EP1373224A1 (en) 2004-01-02
HRP20030740A2 (en) 2005-06-30
PA8541601A1 (es) 2003-05-14
AP2003002857A0 (en) 2003-09-30
WO2002076953A1 (en) 2002-10-03
SK11562003A3 (sk) 2005-01-03
PT1373224E (pt) 2007-09-25
TNSN03076A1 (en) 2005-12-23
EE200300459A (et) 2004-02-16
RS50429B (sr) 2009-12-31
CY1106829T1 (el) 2012-05-23
DE60221233T2 (de) 2008-04-03
JP4086663B2 (ja) 2008-05-14
IL157659A (en) 2008-08-07
PE20021010A1 (es) 2003-02-01
AP1699A (en) 2006-12-26
KR20030086315A (ko) 2003-11-07
YU74003A (sh) 2006-05-25
WO2002074754A1 (en) 2002-09-26
IL157659A0 (en) 2004-03-28
BG108181A (en) 2004-09-30
TWI267509B (en) 2006-12-01
SI1373224T1 (sl) 2007-10-31
DE60221233D1 (de) 2007-08-30
ZA200306601B (en) 2004-08-25
BR0208192A (pt) 2004-03-02
US20040214843A1 (en) 2004-10-28
MXPA03008485A (es) 2003-12-08
KR100617435B1 (ko) 2006-08-31
OA12454A (en) 2004-09-30
CA2441313A1 (en) 2002-09-26
MY142045A (en) 2010-08-30
GEP20053631B (en) 2005-10-10
EA006815B1 (ru) 2006-04-28
ATE367381T1 (de) 2007-08-15
MA27001A1 (fr) 2004-12-20
EP1801106A3 (en) 2007-07-04
NO20034187D0 (no) 2003-09-19
DK1373224T3 (da) 2007-10-15
EA200300906A1 (ru) 2004-02-26
AR033617A1 (es) 2003-12-26
HUP0303637A2 (hu) 2004-03-01
EP1373224B1 (en) 2007-07-18
HK1061854A1 (en) 2004-10-08
EP1801106A2 (en) 2007-06-27
JP2004529123A (ja) 2004-09-24
CN100447136C (zh) 2008-12-31
NZ527847A (en) 2005-06-24
IS6934A (is) 2003-08-29
CA2441313C (en) 2009-03-31
US20070049558A1 (en) 2007-03-01
HUP0303637A3 (en) 2004-07-28
CZ20032451A3 (cs) 2004-09-15
PL367058A1 (en) 2005-02-21
UA74243C2 (uk) 2005-11-15
ES2288552T3 (es) 2008-01-16

Similar Documents

Publication Publication Date Title
ECSP034750A (es) Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
BRPI0412404A (pt) uso de rapamicina e de derivado da rapamicina para o tratamento da perda óssea
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
UY28572A1 (es) Compuestos novedosos
UY29246A1 (es) Nuevos compuestos
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
ECSP066717A (es) Compuestos de quinolina sustituidos
ECSP055525A (es) Inhibidores de cinasas de tirosina
PA8537501A1 (es) Naftostirilos
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
AR026173A1 (es) Inhibidores de neuraminidasas.
UY28342A1 (es) Nuevos compuestos
SV2004001459A (es) 2- (piridin-2-ilamino) -pirido [2,3-d]pirimidin-7-onas ref. pc20501
UY27225A1 (es) Inhibidores de la rho-quinasa
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
UY28946A1 (es) Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
UY29213A1 (es) Derivados de quinolina e isoquinolina 5-sustitiuidos, un procedimiento para su preparación y su uso como inhibidores de la inflamación
CR8135A (es) Triazolopirimidinas
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
UY27219A1 (es) Derivados espirocíclicos nuevos y su uso como inhibidores de fosfodiesterasa-7